1. Home
  2. FINW vs ALXO Comparison

FINW vs ALXO Comparison

Compare FINW & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FinWise Bancorp

FINW

FinWise Bancorp

HOLD

Current Price

$16.79

Market Cap

237.1M

Sector

Finance

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$1.70

Market Cap

240.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FINW
ALXO
Founded
1999
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Commercial Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
237.1M
240.8M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
FINW
ALXO
Price
$16.79
$1.70
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$3.50
AVG Volume (30 Days)
8.4K
771.4K
Earning Date
04-30-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
21.51
26.36
EPS
1.13
N/A
Revenue
N/A
N/A
Revenue This Year
$160.48
N/A
Revenue Next Year
$35.27
N/A
P/E Ratio
$15.35
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.49
$0.41
52 Week High
$22.49
$2.66

Technical Indicators

Market Signals
Indicator
FINW
ALXO
Relative Strength Index (RSI) 56.91 34.25
Support Level $16.39 $1.41
Resistance Level $18.95 $2.30
Average True Range (ATR) 0.54 0.16
MACD 0.21 -0.04
Stochastic Oscillator 73.97 15.08

Price Performance

Historical Comparison
FINW
ALXO

About FINW FinWise Bancorp

FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: